Xcout Intel
Exosome Diagnostics, Inc.
Exosome Diagnostics, Inc. is a molecular diagnostics company located in Massachusetts, United States. The company specializes in developing biofluid-based liquid biopsy tests, such as the ExoDx Prostate test, for use in personalized medicine and oncology.
Subscribe to see Exosome Diagnostics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Exosome Diagnostics, Inc. at a glance
Exosome Diagnostics, Inc. is a diagnostics company headquartered in United States. Its most recent funding round raised $30.3M in June 2017. Xcout tracks 11 named people at Exosome Diagnostics, Inc., including Michael K. McGarrity (Chief Executive Officer, Director).
Exosome Diagnostics, Inc. leadership
- Michael K. McGarrityChief Executive Officer, Director
- Ron KalfusInterim Chief Financial Officer
- John BellanoChief Commercial Officer
- Joseph SolleeExecutive Vice President of Corporate Development and General Counsel
- Kim LerouxExecutive Vice President, Revenue Cycle Management
- Koen HoffmanChairman and Independent Director, representing Ahok BV
5 more named people on record for Exosome Diagnostics, Inc., with roles, board committees and tenure — see the full roster →
Exosome Diagnostics, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $30.3M | — | |
| SEC Form D filing | $15.5M | — | |
| Series B | $44.7M | — | |
| SEC Form D filing | $1.5M | — | |
| Series A | $20M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Exosome Diagnostics, Inc. competitors
A few of Exosome Diagnostics, Inc.'s closest competitors — see the full list of competitors and alternatives →
ExosomeDx (Exosome Diagnostics) develops noninvasive liquid-biopsy diagnostics based on RNA carried in exosomes, including the ExoDx Prostate test for assessing prostate-cancer risk. Its products serve urologists, oncologists, laboratories, and patients by supporting clinical decision-making without relying solely on invasive biopsy.
Nexosome Oncology Holdings, Inc. develops blood tests for early-stage cancer detection using patented extracellular vesicle proteomics and AI/ML biomarker discovery. The company serves patients and healthcare partners by providing highly accurate diagnostic tools.
EcoGenome LLC is a biotechnology company that develops diagnostic tests and kits for cancer, specifically focusing on prostate cancer. The company identifies individual tumor genetic vulnerabilities to help inform precise therapy planning and treatment choices for patients.
Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.
MDxHealth SA is a commercial-stage precision diagnostics company specializing in urological solutions, with operations spanning the United States, the Netherlands, Belgium, Spain, Poland, Italy, the wider European Union, and various other international regions. The firm offers advanced genomic tests for prostate cancer, including SelectMDx, a non-invasive urine diagnostic, and ConfirmMDx, an epigenetic test. These innovative tools enable medical professionals to identify clinically significant prostate cancer while reducing the need for invasive procedures that carry potential complications. Incorporated in 2003, MDxHealth SA is headquartered in Herstal, Belgium, having changed its name from OncoMethylome Sciences SA in October 2010.
Predicine Holdings Ltd provides next-generation liquid biopsy platforms and molecular profiling services for cancer research and precision medicine. The company utilizes proprietary blood- and urine-based assays to analyze circulating tumor DNA and RNA, serving biopharmaceutical partners and clinical researchers in oncology drug development and clinical trials.
Get Exosome Diagnostics, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Exosome Diagnostics, Inc. in Xcout Intel
- 11 named people with titles, LinkedIn and board committees
- 5 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access